Lexaria Bioscience Corp. LEXX Archives - Page 39 of 39

ThursdayJul 15, 2021 12:58 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Completion of Antiviral Drug Molecular Characterization Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced the results of its antiviral drug molecular characterization study. Lexaria worked with the National Research Council (“NRC”), Canada’s premier federally funded research organization, to conduct the study. Results from the NRC confirm the study objectives, including demonstrating that the company’s proprietary DehydraTECH(TM) processing and formulation technology does not create a covalently bonded new molecular entity (“NME”). In addition, the study confirmed that each of the five drugs tested remained stable without undergoing any change in chemical structure. The five drugs included remdesivir, ebastine, bepridil, rupintrivir and colchicine. The…

ThursdayJul 15, 2021 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Commercial Success with its Drug Delivery Technology

Lexaria is making progress with research on its DehydraTECH drug delivery technology Advanced 2nd-generation DehydraTECH 2.0 formulations utilized in ongoing hypertension studies The company intends to monetize its technology for commercial use Its quest for commercial success also follows its move to delist from the Canada Securities Exchange (“CSE”) to focus on the Nasdaq listing Lexaria Bioscience (NASDAQ: LEXX) continues to innovate with its DehydraTECH(TM) drug-delivery technology. It is constantly collaborating with research institutions and businesses to identify other new ways to improve its technology. So far, advanced DehydraTECH 2.0 formulations are already being used by the company in ongoing…

TuesdayJul 13, 2021 11:04 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Considerable IP Portfolio with Patent Protection in Japan

Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced an additional expansion of its intellectual property (“IP”) portfolio with its first-ever patent granted in Japan. According to the update, “Stable ready-to-drink beverage compositions comprising lipophilic active agents” is the title of the patent that adds to the company's considerable portfolio. “With our 20th patent granted worldwide, Lexaria continues to demonstrate the versatility of our DehydraTECH(TM) drug delivery platform, encouraging innovation in the consumable liquid category around the world,” said Chris Bunka, CEO of Lexaria. “This new patent adds to our existing suite of granted…

MondayJul 12, 2021 11:17 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Delists from CSE to Focus Efforts on Most Effective Drug Platform Outcomes

Lexaria Bioscience is a drug bioavailability platform developer intent on providing an effective oral administration alternative to smoking that duplicates the rapid assimilation benefits of inhalation without the lung-harmful effects The company’s DehydraTECH IP is being evaluated for concentration levels, tolerability and ability to transform partner drugs to oral solutions without incidentally creating new molecular entities Lexaria announced voluntary delisting from the Canadian Securities Exchange this month in order to focus its resources more effectively on its Nasdaq listing The company’s leadership recently interacted with investors in the Life Sciences Investor Forum virtual conference series and the company’s annual meeting…

ThursdayJul 08, 2021 11:38 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive Results From its Recent Animal Study on the Effectiveness of its DehydraTECH Drug Delivery Technology

Lexaria Bioscience Corp. announced positive results from its VIRAL-A20-2 study This study showed strong gains in delivery of the DehydraTECH-enabled remdesivir and ebastine among animals The success of this study shows the potential and commercial viability of Lexaria’s DehydraTECH In June 2021, Lexaria Bioscience (NASDAQ: LEXX) announced positive results from its VIRAL-A20-2 study that evaluated the effectiveness of DehydraTECH-enabled remdesivir and ebastine among animals. The results were strongly positive and demonstrated greater effectiveness than in Lexaria’s first antiviral drug study reported in December 2000. The research was a tolerability and pharmacokinetic (“PK”) study involving four groups of 10 animals each.…

TuesdayJul 06, 2021 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) Announces Milestone in Antiviral Delivery Platform Testing

Drug delivery platform developer Lexaria Bioscience has been testing its patented technology in conjunction with antivirals Remdesivir and Ebastine during the past year to determine the potential for enhancing their effectiveness against the COVID-19 virus Early-stage testing has determined Lexaria’s technology — DehydraTECH — did not inhibit Remdesivir and Ebastine in their use against the virus DehydraTECH is a technology that helps drugs gain better bioavailability through effective introduction into patients’ bloodstreams The DehydraTECH platform has also shown great potential in enhancing hypertension medication and additional trials are ongoing Pharmaceutical use and bioavailability innovator Lexaria Bioscience (NASDAQ: LEXX) (CSE: LXX)…

ThursdayJul 01, 2021 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) Announces Status Report on Six Key R&D Programs

Lexaria announced significant strides in six of its studies within the 2021 applied R&D program All the studies are based on Lexaria’s DehydraTECH(TM) technology and are designed for multiple market applications, including oral nicotine, NSAIDs, antivirals, and hypertension The 2021 applied R&D program is intended to generate not only confirmatory results and data evidencing but also foster strategic commercial opportunities and corporate relationships Lexaria Bioscience (NASDAQ: LEXX) (CSE: LXX) released a status report on six of its studies in the 2021 applied research and development (“R&D”) program. The program mainly involves studies using DehydraTECH(TM) 2.0 formulations, with different market areas…

WednesdayJun 30, 2021 10:36 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) Notes Results from 2021 Annual Meeting

Lexaria Bioscience (NASDAQ: LEXX) (CSE: LXX), a global innovator in drug-delivery platforms, has released the results of its annual meeting, which was held June 28, 2021. According to the announcement, the meeting began at 1 p.m. PT with 2,735,413 company shares represented either in person or by proxy; that number constituted 53.6% of the company’s issued share capital as of May 3, 2021. There were several matters voted upon during the meeting, including the election of Chris Bunka, John Docherty, Nicholas Baxter, Ted McKechnie and Albert Reese Jr. as directors, with the percent approving the elections ranging from 82.1% to…

TuesdayJun 29, 2021 9:23 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) Is ‘One to Watch’

Lexaria Bioscience Corp. has disruptive proprietary technology protected by a broad international patent portfolio The company has been issued 19 patents in the U.S., European Union and other countries, with more than 50 patents pending around the world Lexaria’s DehydraTECH technology has a vast worldwide, multi-billion-dollar total addressable market, including multiple rapid-growth segments like cannabinoid and noncombustible nicotine delivery The company has licensed its fat-soluble active molecule delivery technology to multiple established companies for use in their products Lexaria completed an uplisting to Nasdaq Capital Markets and an $11 million financing in January 2021 Lexaria Bioscience (NASDAQ: LEXX) (CSE: LXX)…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LEXX